Involved in the biotechnology industry now or want to be in the future? You should register for the ISPE 2017 Annual Meeting & Expo. This year’s event takes place in sunny San Diego, California from 29 October through 1 November.
Sessions will address groundbreaking new technologies, like antibody drug conjugates, oligonucleotide synthesis, and continuous processing to continuous improvements topics like driving efficiencies and plant utilization to maximize production in existing facilities. The event has over 20 presentations focused on elements important to biotechnology. This is not a surprise as even many large traditional pharma firms are investing significantly in development of biologic products.
A stand-out bio session at the ISPE 2017 Annual Meeting & Expo is “Amgen Singapore Next Generation Manufacturing”, taking place Monday, 30 October, 1345–1515. You will have the opportunity to hear about the 10-year process Amgen went thru to evolve their biotechnology manufacturing platform from large scale stainless steel processing to a next generation all disposable single-use manufacturing facility in Singapore.
Are we at a point where we can provide adaptive mobile Biopharma production suites? Do platform processes allow for (and are we ready for) ‘off-the-shelf’ predesigned biologics facilities? We have a full education agenda with biotechnology sessions that will answer this and more.
Explore the ISPE 2017 Annual Meeting & Expo website to see what other bio-specific advantages are awaiting you in San Diego!
In the pharmaceutical industry, which is highly regulated, aseptic processing is a critical component that ensures the sterility of products. Regulators have a set of comprehensive requirements that minimize the risk of contamination. Regulators set the requirements; however, the industry has an obligation to the patients who rely on and expect a drug that is safe and free of contamination....
Like any investment in digital manufacturing systems, demonstrating business payback before and after investment is critical to getting MES projects approved and verifying profitability after investment. Whether it is introducing MES, expanding it to additional sites, switching software, upgrading existing software, or developing electronic production records (EPR) for new drug products,...
Sustainability is emerging as a pivotal force influencing the pharmaceutical industry’s dynamics and steering companies towards transformative change. The focus of this analysis is to delve into the sustainability key performance indicators (KPIs) of prominent pharmaceutical players, namely Pfizer, Sanofi, Glaxo Smith Kline (GSK), Becton Dickinson, Johnson & Johnson, Abbott, Eli Lilly, and...